Open AccessThis article is
- freely available
µ-Conotoxins as Leads in the Development of New Analgesics
Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia
Received: 9 March 2010; in revised form: 6 April 2010 / Accepted: 12 April 2010 / Published: 19 April 2010
Abstract: Voltage-gated sodium channels (VGSCs) contain a specific binding site for a family of cone shell toxins known as µ-conotoxins. As some VGSCs are involved in pain perception and µ-conotoxins are able to block these channels, µ-conotoxins show considerable potential as analgesics. Recent studies have advanced our understanding of the three-dimensional structures and structure-function relationships of the µ-conotoxins, including their interaction with VGSCs. Truncated peptide analogues of the native toxins have been created in which secondary structure elements are stabilized by non-native linkers such as lactam bridges. Ultimately, it would be desirable to capture the favourable analgesic properties of the native toxins, in particular their potency and channel sub-type selectivity, in non-peptide mimetics. Such mimetics would constitute lead compounds in the development of new therapeutics for the treatment of pain.
Keywords: cone shell; toxin; sodium channel; pain; peptide mimetic
Citations to this Article
Cite This Article
MDPI and ACS Style
Norton, R.S. µ-Conotoxins as Leads in the Development of New Analgesics. Molecules 2010, 15, 2825-2844.
Norton RS. µ-Conotoxins as Leads in the Development of New Analgesics. Molecules. 2010; 15(4):2825-2844.
Norton, Raymond S. 2010. "µ-Conotoxins as Leads in the Development of New Analgesics." Molecules 15, no. 4: 2825-2844.